Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH070727, MH081060, MH066198)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Department of Veterans Affairs | Office of Academic Affiliations, Department of Veterans Affairs (National Center for PTSD)
Yale | YSM | Yale Center for Clinical Investigation, Yale School of Medicine (2UL1TR001863)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (2P50AA012870)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 6 April 2023
Revised: 29 May 2023
Accepted: 4 June 2023
First Online: 24 July 2023
Competing interests
: 2023 Financial Disclosure: JHK, MD; Consultant: Note: – These Individual Consultant Agreements listed below are less than $5000 per year; Aptinyx, Inc.; Biogen, Idec, MA; Bionomics, Limited (Australia); Boehringer Ingelheim International; Epiodyne, Inc.; EpiVario, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Spring Care, Inc.; Sunovion Pharmaceuticals, Inc. Co-Founder: Freedom Biosciences, Inc. Scientific Advisory Board: Biohaven Pharmaceuticals; BioXcel Therapeutics, Inc. (Clinical Advisory Board); Cerevel Therapeutics, LLC; Delix Therapeutics, Inc.; Eisai, Inc.; EpiVario, Inc.; Jazz Pharmaceuticals, Inc.; Neumora Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corporation; PsychoGenics, Inc.; Takeda Pharmaceuticals; Tempero Bio, Inc.; Terran Biosciences, Inc. Stock: Biohaven Pharmaceuticals; Freedom Biosciences; Spring Health, Inc. Stock Options: Biohaven Pharmaceuticals Medical Sciences; Cartego Therapeutics; Damona Pharmaceuticals; Delix Therapeutics; EpiVario, Inc.; Neumora Therapeutics, Inc.; Rest Therapeutics; Tempero Bio, Inc.; Terran Biosciences, Inc.; Tetricus, Inc. Income Greater than $10,000: Editorial Board - Editor - Biological Psychiatry. Patents and Inventions: 1. Seibyl JP, JHK, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948.September 5, 1995; 2. Vladimir, Coric, JHK, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017; 3. Charney D, JHK, Manji H, Matthew S, Zarate C., - Intranasal Administration of Ketamine to Treat Depression United States Patent Number: 9592207, Issue date: 3/14/2017. Licensed to Janssen Research & Development; 4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, JHK, Yale University “Methods for Treating Suicidal Ideation”, Patent Application No. 15/379,013 filed on December 14, 2016 by Yale University Office of Cooperative Research; 5. Arias A, Petrakis I, JHK – Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research. 6. Chekroud, A., Gueorguieva, R., & JHK. “Treatment Selection for Major Depressive Disorder” [filing date 3<sup>rd</sup> June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University; 7. Gihyun, Yoon, Petrakis I, JHK – Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01; 8. Abdallah, C, JHK, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719,935 filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01; 9. JHKl, Godfrey Pearlson, Stephanie O’Malley, Marc Potenza, Fabrizio Gasparini, Baltazar Gomez-Mancilla, Vincent Malaterre. Mavoglurant in treating gambling and gaming disorders. U.S. Provisional Patent Application No. 63/125,181filed on December 14, 2020 by Yale University Office of Cooperative Research OCR 8065 US00. NON Federal Research Support: AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant “Center for Translational Neuroscience of Alcoholism [CTNA-4]; Novartis provides the drug, Mavoglurant, for research related to NIAAA grant “Center for Translational Neuroscience of Alcoholism [CTNA-4]; Cerevel provides the drug PF-06412562 for A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia (1 U01 MH121766-01). JMM -2023 Disclosures: Scientific Advisory Board: Gilgamesh. Income Greater than $10,000: Editorial Board – Co-Principal Editor Neuropsychopharmacology. ETK – 2023 Disclosures: No Disclosures.